Merkezi ve periferik olarak enjekte edilen CDP-kolin’in sıçanlarda plazma nesfatin-1 seviyesi üzerine etkisi

Abstract

Nesfatin-1, iştah regülasyonunda ve enerji homeostazında rol oynar. Kolinerjik sistemin aktivitesi de beslenme davranışını etkileyebilir. Ayrıca, merkezi kolinerjik ve nesfatinerjik sistemler arasında bir etkileşim vardır. Bu çalışmada homojen sayıda erkek ve dişi aç bırakılmış ve tok Wistar albino sıçanlara, serebral yan ventrikül (syv) ve intravenöz (iv) uygulanmış CDP-kolinin (0.5 ve 1 μmol; syv ve 250 mg / kg; iv) plazma nesfatin-1 düzeylerine etkisinin belirlenmesi amaçlanmıştır. Sevofluran (% 2-4 /% 100 O2) anestezisi altında, sıçanların karotis arteri kan örnekleri toplamak için ve juguler veni ise iv enjeksiyon yapmak için kanüle edildi. Syv enjeksiyonlar için ise sıçanların lateral ventrikülüne kılavuz kanül yerleştirildi. Tok sıçanların bazal plazma nesfatin-1 seviyeleri, aç bırakılan hayvanlardakinden daha yüksek olarak gözlendi. 0.5 ve 1 μmol dozunda syv ve / veya 250 mg / kg dozunda iv enjekte edilen CDP-kolin, tok sıçanlarda plazma nesfatin-1 seviyelerini artırırken, aynı doz ve yolla CDP-kolin uygulaması, aç bırakılan hayvanların plazma nesfatin-1 düzeylerini azalttı. Sonuçlar, CDP-kolinin sıçanlarda plazma nesfatin-1 seviyelerini etkileyebileceğini göstermektedir. İlacın etkisi sıçanların besin alımına göre farklılık göstermektedir. Bu veriler, CDP-kolinin plazma nesfatin-1 konsantrasyonu üzerinde potansiyel etkisi olabileceğini göstermektedir.

Keywords

• CDP-kolin,serebral yan ventrikül,intravenöz,plazma nesfatin-1

The effect of centrally and peripherally injected CDP-choline on plasma nesfatin-1 level in rats

Abstract

Nesfatin-1 has a role in appetite control and energy balance. The activity of the cholinergic system also is able to affect feeding behavior. Moreover, the central cholinergic system interacts with central nesfatinergic systems. The main goal of the study was to determine the effect of intracerebroventricular (icv) and intravenous (iv) administrated CDP-choline (0.5 ve 1 μmol; icv ve 250 mg / kg; iv) on levels of plasma nesfatin-1 in the homogeneous number of male and female fasted and the satiated Wistar albino rats. The polyethylene cannula was inserted into the carotid artery and jugular vein of the rats anesthetized with sevoflurane (2–4%/100% O2) to collect blood samples and to make iv injection, respectively. For icv treatment, the lateral ventricle of rats was cannulated with guide cannula. The basal levels of plasma nesfatin-1 in the satiated rats were higher than those observed in the fasted animals. While 0.5 and 1 μmol dose of icv and/or 250 mg/kg dose of iv injected CDP-choline increased the level of plasma nesfatin-1 in the satiated rats, plasma nesfatin-1 level of the fasted animals decreased after the same dose and route of CDP-choline injection. The current findings show that CDP-choline can influence the level of plasma nesfatin-1 in the rats. The effect of the drug was different according to the food intake of the rats. These data might suggest a potential role in CDP-choline on plasma nesfatin-1 concentration.

Keywords

• CDP-choline,Plasma nesfatin-1,Intracerebroventricular,Intravenous

References

1. Algul S, Ozkan Y, Ozcelik O (2016): Serum nesfatin-1 levels in patients with different glucose tolerance levels. Physiol Res, 65, 979-985.
2. Aydin B, Guvenc G, Altinbas B, et al. (2018): Modulation of nesfatin-1-induced cardiovascular effects by the central cholinergic system. Neuropeptides, 70, 9-15.
3. Cansev M, Ilcol YO, Yilmaz MS, et al. (2008): Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations. Auton Autacoid Pharmacol, 28, 41-58.
4. Cohen EL, Wurtman RJ (1976): Brain acetylcholine: control by dietary choline. Science, 191, 561–562.
5. Darambazar G, Nakata M, Okada T, et al. (2015): Paraventricular NUCB2/nesfatin-1 is directly targeted by leptin and mediates its anorexigenic effect. Biochem Biophys Res Commun, 456, 913-918.
6. Davalos A, Secades J (2011): Citicoline preclinical and clinical update 2009-2010. Stroke, 42, 36-39.
7. Gantulga D, Maejima Y, Nakata M, et al. (2012): Glucose and insulin induce Ca2+ signaling in nesfatin-1 neurons in the hypothalamic paraventricular nucleus. Biochem Biophys Res Commun, 420, 811-815.
8. Gil K, Bugajski A, Kurnik M, et al. (2012): Chronic vagus nerve stimulation reduces body fat, blood cholesterol and triglyceride levels in rats fed a high-fat diet. Folia Med Cracov, 52, 79-96.

9. Goebel-Stengel M, Wang L, Stengel A, et al. (2011): Localization of nesfatin-1 neurons in the mouse brain and functional implication. Brain Res, 1396, 20-34.
10. Gurun MS, Ilcol YO, Taga Y, et al. (2002): Hyperglycemia induced by intracerebroventricular choline: involvement of the sympatho-adrenal system. Eur J Pharmacol, 438, 197-205.
11. Hurtado O, Lizasoain I, Moro MA (2011): Neuroprotection and recovery: recent data at the bench on citicoline. Stroke, 42, 33-35.
12. Ilcol YO, Cansev M, Yilmaz MS, et al. (2007): Intraperitoneal administration of CDP-choline and its cholinergic and pyrimidinergic metabolites induce hyperglycemia in rats: involvement of the sympathoadrenal system. Arch Physiol Biochem, 113, 186-201.
13. Ilcol YO, Gurun MS, Taga Y, et al. (2002): Intraperitoneal administration of choline increases serum glucose in rat: involvement of the sympathoadrenal system. Horm Metab Res, 34, 341-347.
14. Killgore WD, Ross AJ, Kamiya T, et al. (2010): Citicoline affects appetite and cortico-limbic responses to images of high17 calorie foods. Int J Eat Disord, 43, 6-13.
15. Kiyici S, Basaran NF, Cavun S, et al. (2015): Central injection of CDP-choline suppresses serum ghrelin levels while increasing serum leptin levels in rats. Eur J Pharmacol, 764, 264-270.
16. Kohno D, Nakata M, Maejima Y, et al. (2008): Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology, 149, 1295-1301.
17. Li QC, Wang HY, Chen X, et al. (2010): Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept, 59, 72-77.
18. Lopez G-Coviella I, Agut J, Von Borstel R, et al. (1987): Metabolism of cytidine (5ʹ)-diphosphocholine (CDP-choline) following oral and intravenous administiration to the human and the rat. Neurochem Int, 11, 293-297.
19. Lopez-Coviella I, Agut J, Savci V, et al. (1995): Evidence that 5ʹ-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. Neurochem, 65, 889-894.
20. Macro JA, Dimaline R, Dockray GJ (1996): Identification and expression of prohormoneconverting enzymes in the rat stomach. Am J Physiol, 270, 87-93.
21. Mason WT (1985): Staining of the magnocellular nuclei of the rat hypothalamus by a monoclonal antibody directed against the alpha-subunit of the nicotinic cholinergic receptor. Neurosci Lett, 59, 89-95.
22. Michels KM, Meeker RB, Hayward JN (1986): Differential distribution of muscarinic cholinergic and putative nicotinic cholinergic receptors within the hypothalamo-neurohypophysial system of the rat. Neuroendocrinology, 44, 498-507.
23. Oh-I S, Shimizu H, Satoh T, et al. (2006): Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature, 12, 709-712.
24. Ozkan Y, Timurkan ES, Aydin S, et al. (2013): Acylated and desacylated ghrelin, preptin, leptin, and nesfatin-1 Peptide changes related to the body mass index. Int J Endocrinol, 2013, 236085.
25. Paroni R, Cighetti G, Del Puppo M, et al. (1985): Evidence for a different metabolic behaviour of cytidine diphosphate choline after oral and intravenous administration to rats. Pharmacol. Res Commun, 17, 805-829.
26. Ramanjaneya M, Chen J, Brown JE, et al. (2010): Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology, 151, 3169-3180.
27. Savci V, Cavun S, Goktalay G, et al. (2002): Cardiovascular effects of intracerebroventricularly injected CDP-choline in normotensive and hypotensive animals: the involvement of cholinergic system. Naunyn Schmiedebergs Arch Pharmacol, 365, 388-398.
28. Savci V, Goktalay G, Cansev M, et al. (2003): Intravenously injected CDP-choline increases blood pressure and reverses hypotension in haemorrhagic shock: effect is mediated by central cholinergic activation. Eur J Pharmacol, 468, 129-139.
29. Secades JJ, Frontera G (1995): CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol, 17, 1-54.
30. Sevim Ç, Altinbaş B, Yalçın M, et al. (2017): Protective effect of CDP-choline on hypotension and tissue injury in septic shock model. Ankara Üniv Vet Fak Derg, 64, 103-110.
31. Stengel A, Goebel M, Yakubov I, et al. (2009): Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology, 150, 232-238.
32. Topuz BB, Altinbas B, Yilmaz MS, et al. (2014): The effect of centrally injected CDP-choline on respiratory system; involvement of phospholipase to thromboxane signaling pathway. Respir Physiol Neurobiol, 195, 50-58.
33. Ulus IH, Wurtman RJ, Mauron C, et al. (1989): Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. Brain Res, 484, 217-227.
34. Weiss GB (1995): Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci, 56, 637-660.
35. Wurtman RJ, Regan M, Ulus I, et al. (2000): Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol, 60, 989-992.